Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison

Aim To assess the efficacy and safety of iGlarLixi, a fixed‐ratio combination of basal insulin glargine 100 U/mL and lixisenatide (glucagon‐like peptide‐1 receptor agonist) versus IDegAsp, a co‐formulation of basal insulin degludec 100 U/mL with rapid‐acting insulin aspart. Materials and Methods A systematic literature search of randomized controlled trials (RCTs) was performed. Outcomes from eligible RCTs were compared by an indirect treatment comparison using a Bayesian framework. Subanalyses of Japanese and international trials were performed. Results Eight RCTs (duration 26‐30 weeks) were included. Mean difference in HbA1c change with iGlarLixi exceeded that for IDegAsp: −0.64 (95% credible interval −1.01, −0.28) %‐units (−7.0 [−11.0, −3.1] mmol/mol) for all trials, −0.39 (−0.55, −0.23) %‐units (−4.3 [−6.0, −2.5] mmol/mol) for international, and −0.88 (−1.11, −0.64) %‐units (−9.6 [−12.1, −7.0] mmol/mol) for Japanese trials. HbA1c target achievement (